United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

central texas community health centers - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin 250 mg - paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (note-it is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. to reduce the development of drug-resistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs, paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - paromomycin sulfate (unii: 845nu6gjps) (paromomycin - unii:61jjc8n5zk) - paromomycin sulfate is indicated for intestinal amebiasis—acute and chronic (note—it is not effective in extraintestinal amebiasis); management of hepatic coma—as adjunctive therapy. paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. it is also contraindicated in intestinal obstruction.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 g - neomycin and polymyxin b sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infect

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 ml - neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infective drugs in this produ

United States - English - NLM (National Library of Medicine)

stat rx usa llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 ml - neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infective drugs in this produ

United States - English - NLM (National Library of Medicine)

stat rx usa llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i) - neomycin sulfate 3.5 mg in 1 g - neomycin and polymyxin b sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. neomycin and polymyxin b sulfates and bacitracin zinc ophthalmic ointment is contraindicated in those individuals who have shown hypersensitivity to any of its components.